REGENICS AT EVENTS

June 5-6th 2017

Investor Conference Biotech-Medtech, at Stavanger Forum Oslo

Program (tbd)

March 9th 2017

Roundtable Conference in investing in Biotech, CEO Henrik Lund, moderator for the Event at Stavanger Forum Oslo

Program Roundtable Conference Stavanger

March 8th 2017

War on Cancer Nordics, CEO Henrik Lund participating in closing panel at the Economist Event in Oslo

Program Economist Event Oslo

December 15th 2016

DnB Healtcare Conference 2016, CMO Christian Clemm provides company update in the ventture session

Regenics presentation   

October 19-20-21 2016

Biomarine Convention, CEO Henrik Lund, participating at Convention in Oslo

Program Biomarine Business Conference

October 19th 2016

DnB Next at Oslo Innovation Week, CSO Gry Lønne, presenting Regenics Company update in Oslo

program DNB Next healthcare      Regenics presentation 

September 25-28 2016

At the 4th Congress on Innovation in Drug Delivery in Antibes, Regenics publish data on its carrier/vehicle GMO to be used in the CE marking device for wound healing.

Abstract 4th Congress on Innovation in Drug Delivery

October 22-24 2015

At the Joint Meeting of the European Tissue Repair Society (ETRS) and the Wound Healing Society (WHS), Regenics showed excellent and rapid wound healing of its wound healing device Vernex under development for CE-marking in 2018. In 2nd degree burn wounds Vernex provided rapid and complete reepitelialization of epidemal keratinocytes in human explanted skin. This represent a prooof of priciple for the utility of Vernex in human wound healing. 

Abstract 7th ETRS-WHS meeting

Regenics AS has developed a number of assays and techniques to study effects of various substances on skin cells both in vitroin vivo and in the clinic. Our focus is to develop products and techniques for therapeutic skin applications and to improve skin appearance.